Navigation Links
Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
Date:1/22/2008

from baseline in the key secondary clinical outcome variables.

NEBIDO was well-tolerated as indicated by the analysis of the safety measurements collected and the persistence with study treatment. Further, the spectrum of adverse events reported were comparable to other injectable hypogonadism treatments reported in the literature. There were no significant adverse changes in laboratory parameters with NEBIDO treatment.

About NEBIDO

NEBIDO(R) is a long-acting depot preparation of testosterone undecanoate under development for the treatment of male hypogonadism. NEBIDO is expected to be the first long-acting testosterone preparation available in the U.S. in the growing market for testosterone replacement therapies. Indevus acquired U.S. rights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005.

About Hypogonadism

Male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes. Reduced testosterone levels can lead to health problems and significantly impair quality of life. Common effects of hypogonadism include decreased sexual desire, erectile dysfunction, fatigue, muscle loss and weakness, depression, as well as an increased risk of osteoporosis. Today, there are an estimated four to five million men in the U.S. who suffer from hypogonadism. Of this group, less than ten percent are currently receiving treatment with testosterone replacement therapy.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA XR(TM) and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multipl
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Submission of New Drug Application
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/24/2014)... response to the epidemic of prescription opioid overdose deaths ... of Medicine by leaders of agencies in the ... commentary calls upon health care providers to expand their ... overdose deaths, and describes a number of misperceptions that ... commentary also discusses how medications can be used in ...
(Date:4/24/2014)... better to give than to receive at least if ... suggests. , The study found that 15- and 16-year-olds who ... to family members, are less likely to become depressed than ... keeping the money for themselves. , The researchers detail their ... Sciences . , The study focused on the ventral striatum, ...
(Date:4/24/2014)... awarded one of 30 grants from the National Cancer ... Site in its new National Clinical Trials Network ... of investigators charged with distributing resources in a more ... system reflects recommendations from a 2010 Institute of ... goals:, Faster design, launch, and completion of ...
(Date:4/24/2014)... Science Foundation has awarded LSU Health Sciences Center ... Site grant in the amount of $295,635. The ... diverse social and educational backgrounds, underrepresented in the ... The project will provide students with training for ... It will be led by Principal Investigator Dr. ...
(Date:4/24/2014)... research led by a scientist at the University of ... element in the development of the nervous system may ... breast cancer., A research team, led by Dr ... Department of Biology at York, has studied how voltage-gated ... These channels are found in the membranes of excitable ...
Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2
... the Yerkes National Primate Research Center, Emory University, developed ... infrared eye tracking to detect mild cognitive impairment (MCI) ... be helpful in predicting the onset of Alzheimer,s disease. ... issue of The American Journal of Alzheimer,s Disease ...
... a recent survey by the American Academy of Otolaryngology ... America,s ear, nose, and throat (ENT) doctors, many Americans ... obstacle a singer on American Idol has to overcome, ... Americans also strongly agree about the steps necessary to ...
... YORK, April 15 An annual conference on thyroid cancer ... April 15, to focus on the state-of-the-art treatment of thyroid ... exposed to radiation after the Chernobyl nuclear accident in Ukraine ... The New York Eye and Ear Infirmary (NYEEI) ...
... 15 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) ... obtained the HAS certificate (Halal Assurance system) issued by ... and A+C Meningococcal Polysaccharide Vaccine and Flu vaccine. Mr. ... export all our products to all the Muslim countries. ...
... shipment on Thursday, April 16th at 9:30 a.m.DERBY, Conn., ... cases (27,900 cans, jars, packages) of food to the ... Griffin Hospital serves a six-town region in South Central ... be delivered by tractor trailer in one shipment to ...
... Bring Better Quality of Care and Improved Business ... Vocollect Healthcare Systems, Inc. and Pathway Health ... company for the long-term care, senior housing, assisted ... whereby Pathway Health Services will become a solution ...
Cached Medicine News:Health News:Yerkes researchers use eye tracking to detect mild dementia in humans 2Health News:Survey research shows many Americans are aware of importance of voice care 2Health News:Survey research shows many Americans are aware of importance of voice care 3Health News:'Living With Radiation' Conference Commemorating Chernobyl Nuclear Disaster Held at United Nations, Sponsored by New York Eye & Ear Infirmary 2Health News:Hard To Treat Diseases (HTDS) Obtains HAS Certificate 2Health News:Community Food Banks and Homeless Shelter to Receive Gift of 1,649 Cases of Food from Griffin Hospital Employees 2Health News:Pathway Health Services and Vocollect Healthcare Systems Announce Strategic Partnership 2
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
... an immunometric ('sandwich') EIA for the ... serum or plasma. LH in the ... anti-LH antibodies directed at different epitopes. ... particles and the other is labelled ...
... is a glycoprotein secreted by the anterior ... TSH, the intact LH molecule is a ... glycoproteins all have homologous alpha-subunits, however each ... and FSH production and secretion are stimulated ...
Microwell-EIA for the detection of GAD Autoantibody....
Medicine Products: